Symptomatic hypervolemic Hyponatremia
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB06212 | Tolvaptan | A selective vasopressin V2-receptor antagonist to slow kidney function decline in patients at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Also used to treat hypervolemic and euvolemic hyponatremia. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB06212 | Tolvaptan | Vasopressin V2 receptor | target |
| DB06212 | Tolvaptan | Cytochrome P450 3A4 | enzyme |
| DB06212 | Tolvaptan | P-glycoprotein 1 | transporter |
| DB06212 | Tolvaptan | Vasopressin V1a receptor | target |
| Drug | Drug Name | Phase | Status | Count |
|---|